Journal Browser

► Journal Browser

Special Issue Editors

Dr. Jin-Jian Lu

E-Mail Website
Guest Editor

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa, Macao 999078, China
Interests: natural products; cancer; combination therapy; immune microenvironment; resistance; inflammation; cell death

Dr. Le-Le Zhang

E-Mail Website
Guest Editor

School of Basic Medical Sciences, Chengdu University, Chengdu 610106, China
Interests: natural products; cancer; inflammation; pulmonary fibrosis

Dr. Jingjing Li

E-Mail Website
Guest Editor

Department of Rehabilitation Sciences, Faculty of Health and Social Sciences, Hong Kong Polytechnic University, Hong Kong, China
Interests: phytomedicine; angiogenesis; tumor-associated macrophages; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inflammation is a complex biological process triggered by the immune system in response to harmful stimuli, including pathogens, toxic agents, irritants, etc. Uncontrolled inflammation has been proven to be closely related with the pathogenesis of many diseases, including oncological disorders, colitis, metabolic disorders, neurological system diseases, and so on. Therapeutics based on the regulation of inflammation/immune responses have received more and more attention in the treatment of relevant diseases. Nevertheless, great challenges still remain in the discovery of effective therapeutic targets and drug candidates. Natural derived compounds with rich resources and enormous structural diversity provide an enormous library of chemical entities with various biological activities; the discovery of natural bioactive compounds for the regulation of uncontrolled inflammation as well as the treatment of diseases, including oncological disorders, has gained increasing attention in the past decades.

In this Special Issue, entitled "Natural Bioactive Compounds for the Treatment of Inflammation and Oncological Disorders”, we sincerely invite researchers to submit related research results to us, aiming to promote the field of drugs developed from natural products. In particular, studies that evaluate the molecular mechanisms of natural bioactive compounds in the treatment of inflammation-related diseases and oncological disorders are especially encouraged. Both original research articles and reviews are welcome.

Dr. Jin-Jian Lu
Dr. Le-Le Zhang
Dr. Jingjing Li
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

natural compounds
inflammation
oncological disorders
molecular mechanisms

Published Papers (1 paper)

Research

17 pages, 4382 KiB

Open AccessArticle

Dihydrotanshinone Triggers Porimin-Dependent Oncosis by ROS-Mediated Mitochondrial Dysfunction in Non-Small-Cell Lung Cancer

by Dongjie Zhang, Renyikun Yuan, Jiaping Pan, Qiumei Fan, Kaili Sun, Zhipeng Xu, Xiang Gao, Qinqin Wang, Jia He, Yaqing Ye, Zhengrong Mu, Jing Leng and Hongwei Gao

Int. J. Mol. Sci. 2023, 24(15), 11953; https://doi.org/10.3390/ijms241511953 - 26 Jul 2023

Viewed by 1239

Abstract

Lung cancer is one of the leading causes of cancer death. Non-small-cell lung cancer (NSCLC) accounts for the majority of lung cancer diagnoses. Dihydrotanshinone (DHT) is a compound extract from Salvia miltiorrhiza, which has favorable anti-inflammatory and anti-cancer activities. However, the role of DHT in NSCLC has not been fully studied. The anti-cancer drugs used for treating lung cancer often lead to apoptosis; however, the drug resistance of apoptosis restricts the effect of these drugs. Oncosis is a passive form of cell death that is different from apoptosis. It is characterized by cell swelling, and Porimin is a specific marker for oncosis. In this study, the role of DHT in mediating oncosis in A549 cells was investigated. In vitro, the MTS assay was used to detect cell activity after DHT treatment. Microscopy and electron microscopy were used to observe cell morphology changes. Western blotting was used to detect protein expression. Flow cytometry was used to detect intracellular reactive oxygen species (ROS) level, calcium ion (Ca²⁺) level, and cell mortality. The intracellular Lactic dehydrogenase (LDH) level was detected by an LDH detection kit after DHT treatment. The ATP level was detected using an ATP detection kit. In vivo, Lewis lung cancer (LLC) xenograft mice were used to evaluate the anti-tumor effect of DHT. Hematoxylin and eosin (HE) staining was used to detect the pathology of lung cancer tumors. The detection of Porimin in the tumor tissues of the mice after DHT administration was assessed by immunohistochemistry (IHC). The results of this study showed that DHT treatment changed the cell morphology; destroyed the mitochondrial structure; increased the expression of Porimin; increased the levels of LDH, ROS, and Ca²⁺; decreased the mitochondrial membrane potential and ATP level; and played an anti-tumor role in vitro by mediating oncosis in A549 cells. The in vivo studies showed that DHT could effectively inhibit tumor growth. The results of protein detection and IHC detection in the tumor tissues showed that the expression of Porimin was increased and that oncosis occurred in the tumor tissues of mice. DHT triggered Porimin-dependent oncosis by ROS-mediated mitochondrial dysfunction in NSCLC. The in vivo studies showed that DHT could inhibit tumor growth in LLC xenograft mice by triggering oncosis. This study indicates the potential for DHT to treat NSCLC. Full article

(This article belongs to the Special Issue Natural Bioactive Compounds for the Treatment of Inflammation and Oncological Disorders)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Natural Bioactive Compounds for the Treatment of Inflammation and Oncological Disorders

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (1 paper)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI